Royalty Pharma plc has grown revenue 2.4% a year over three years and 2.5% a year over five, with earnings per share compounding at 52%. Revenue growth, 3-year annual rate: +2.4% (Biotechnology median +17%). Revenue growth, 5-year rate: +2.5%, growth has slowed since the five-year average. Earnings per share, 3-year rate: +52%, earnings outgrew revenue: margins or the share count worked for shareholders. Years of annual history on file: 8, FY2018 to FY2025, as filed.

RPRXRoyalty Pharma plc

Healthcare

$56.90+59% 1Y

$56.90

$34.3752 weeks$63.98

Is it growing?

Mixed

Neither accelerating nor breaking down: revenue growing +10% year on year, but earnings down −18% year on year and operating margin narrowing (−19.9 points).

1 good, 2 to watch

Revenue trend+10% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +3% a year.

Earnings trend−18% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.

Margin direction−19.9 points operating

Trailing-twelve-month operating margin, 60.4% now against 80.3% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is RPRX growing?

Royalty Pharma plc has grown revenue 2.4% a year over three years and 2.5% a year over five, with earnings per share compounding at 52%.

+2.4%

Revenue growth, 3-year annual rate · Biotechnology median +17% · growing slowly · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +2.5%
Revenue growth, 5-year rate · +2.4% over three · growth has slowed since the five-year average
Earnings per share, 3-year rate: +52%
Earnings per share, 3-year rate · revenue +2.4% · earnings outgrew revenue: margins or the share count worked for shareholders
Years of annual history on file: 8
Years of annual history on file · FY2018 to FY2025, as filed